Douglas Evan Godshall - 22 Jun 2021 Form 4 Insider Report for EyePoint Pharmaceuticals, Inc. (EYPT)

Role
Director
Signature
/s/ Ron Honig, Attorney-in-Fact
Issuer symbol
EYPT
Transactions as of
22 Jun 2021
Net transactions value
$0
Form type
4
Filing time
23 Jun 2021, 17:39:50 UTC
Previous filing
20 May 2021
Next filing
20 Aug 2021
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction EYPT Common Stock Options Exercise $0 +2,500 +45% $0.000000 8,016 22 Jun 2021 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction EYPT Restricted Stock Units Options Exercise $0 +2,500 $0.000000* 0 22 Jun 2021 Common Stock 2,500 $0.000000 Direct F1, F2
transaction EYPT Stock Option (Right to Buy) Award $0 +11,000 $0.000000 11,000 22 Jun 2021 Common Stock 11,000 $13.13 Direct F1, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Douglas Evan Godshall is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may continue.

Explanation of Responses:

Id Content
F1 The grants were approved by the Compensation Committee on February 9, 2021, subject to stockholder approval of an amendment to increase the number of shares in the Company's 2016 Plan. The shareholders approved the amendment on June 22, 2021.
F2 The Restricted Stock grant vested immediately upon Mr. Godshall's departure from the Board on June 22, 2021.
F3 The option to purchase vested immediately upon Mr. Godshall's departure from the Board on June 22, 2021.